Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a

Title:Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a

Volume: 17 Issue: 2

Author(s): Mohsen Ebrahimimonfared, Ali Ganji, Sara Zahedi, Parisa Nourbakhsh, Keyvan Ghasami and Ghasem Mosayebi*

Affiliation:

• Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak,Iran

Keywords: Interferon beta-1a, multiple sclerosis, regulatory T-cells, myelin, sheath, CNS, Treg cells.

Abstract: Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described.

Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS.

Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects.

Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.

Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.

Cite this article as:

Ebrahimimonfared Mohsen , Ganji Ali , Zahedi Sara, Nourbakhsh Parisa , Ghasami Keyvan and Mosayebi Ghasem *, Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a, CNS & Neurological Disorders - Drug Targets 2018; 17 (2) . https://dx.doi.org/10.2174/1871527317666180327122435